Back to Journals » OncoTargets and Therapy » Volume 10
Original Research
VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
8,560 | Dovepress* | 7,453+ | 1,425 | 8,878 | |
PubMed Central* | 1,107 | 284 | 1,391 | ||
Totals | 8,560 | 1,709 | 10,269 | ||
*Since 6 January 2017 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
4 | 0 | 0 | 0 | 2 | 2 |
View citations on PubMed Central and Google Scholar